Related by context. All words. (Click for frequent words.) 73 AEG# 71 FOLOTYN ® 70 HDAC Inhibitor 70 Afatinib 70 Granulocyte Colony Stimulating Factor 70 receptor tyrosine kinase inhibitor 70 sorafenib tablets 70 Epratuzumab 69 Sapacitabine 69 Lubiprostone 69 CYT# potent vascular disrupting 69 Hsp# Inhibitor 69 Epidermal Growth Factor Receptor 69 Meets Primary Endpoint 69 Phase III Clinical Trial 69 Archexin 69 XYOTAX TM 69 Pemetrexed 69 Methylnaltrexone 68 Advanced Renal Cell 68 pan HDAC inhibitor 68 metastatic colorectal 68 Malignant Melanoma 68 Irinotecan 68 EGFR HER2 68 mertansine 68 Daclizumab 68 Safinamide 68 Aplidin R 68 YONDELIS R 68 Amrubicin 68 oral prodrug 68 PKC# 68 Myocet 68 erlotinib Tarceva ® 68 AKT inhibitor 68 EOquin TM 68 Yondelis ® 67 Successfully Completes Phase 67 Ozarelix 67 YONDELIS 67 Perifosine 67 nucleoside analog 67 MAGE A3 ASCI 67 Kinase Inhibitor 67 Darinaparsin 67 Pafuramidine 67 Voreloxin 67 Hepatocellular Carcinoma 67 Prolongs Survival 67 dasatinib Sprycel ® 67 INSPIRE Trial Phase III 67 ThermoDox R 67 Aflibercept 67 iobenguane 67 Immunotherapeutic 67 OMP #M# 67 ARRY # 67 novel VDA molecule 67 Xanafide 67 Tamibarotene 67 systemic antifungal 67 UPLYSO 67 Oral Formulation 67 oral Janus kinase 67 Degarelix 67 Fulvestrant 67 MORAb 67 Azilect ® 67 Novel Oral 67 Blinatumomab 67 metaglidasen 66 Intravenous CP 66 chimeric monoclonal antibody 66 myelofibrosis polycythemia vera 66 Antitumor 66 targeting CD# 66 Glufosfamide 66 IAP inhibitors 66 Aplidin 66 ZK EPO 66 Initiate Clinical Trial 66 Aviptadil 66 MGd 66 Cloretazine 66 HuMax TAC 66 bendamustine HCl 66 Panzem R NCD 66 Systemic Delivery 66 Exelixis XL# 66 Pralatrexate 66 Hormone Refractory Prostate Cancer 66 metastatic neuroendocrine tumors 66 Granted Orphan Drug 66 antibody MAb 66 Insegia 66 Eribulin 66 IL# PE#QQR 66 Phase III Clinical Trials 66 CD# monoclonal antibody 66 Adjuvant Treatment 66 Anti Tumor 66 Cutaneous T 66 PSMA ADC 66 Cetrorelix 66 hepatocellular carcinoma HCC 66 Metastatic Colorectal Cancer 66 Virulizin ® 66 Phase 2b Clinical Trial 66 Bavituximab 66 Vicinium TM 66 Phase Ib II 66 Receives Orphan Drug Designation 66 protein tyrosine phosphatase 1B 66 JAK Inhibitor 66 Nexavar ® 66 Paraplatin ® 66 HuLuc# 66 Golimumab 66 Initiates Phase II 66 DU #b 66 Antitumor Activity 66 Onconase 66 Ridaforolimus 66 oral antiviral 66 CEQ# 66 XL# XL# 66 Traficet EN 66 Ceflatonin R 66 CTAP# Capsules 66 MEK Inhibitor 66 Proxinium TM 66 Phase #b/#a clinical 66 Bortezomib 66 Annamycin 66 GW# [003] 66 IMiDs 66 Initiates Clinical 66 Oral Fingolimod 66 Drug Candidate 66 Deferiprone 66 AQ4N 65 Marqibo TM 65 Nilotinib 65 mapatumumab 65 Diabetic Macular Edema 65 docetaxel Taxotere ® 65 HuMax EGFr 65 Pirfenidone 65 Phase 2a Trial 65 First Patient Dosed 65 Orally administered 65 Investigational Treatment 65 bevacizumab Avastin ® 65 IMA# 65 recurrent NSCLC 65 Pivotal Phase III 65 antineoplastic 65 huC# DM4 65 kidney urologic 65 Tezampanel 65 NS4A 65 Bosutinib 65 Elotuzumab 65 IMiDs R 65 TMC# [002] 65 IMiDs ® compound 65 histone deacetylase HDAC inhibitor 65 Advanced Melanoma 65 gefitinib Iressa 65 diarrhea predominant irritable 65 lymphoid malignancies 65 forodesine 65 Panzem 65 Phase III Pivotal 65 Poly ICLC 65 SNT MC# 65 Vidofludimus 65 Mitoxantrone 65 familial amyloidotic polyneuropathy FAP 65 Bevacizumab 65 Tasimelteon 65 SUTENT ® 65 Recombinant Human 65 Sevelamer 65 Personalized Immunotherapy 65 JAK2 Inhibitor 65 hormone LHRH antagonist 65 Aurora Kinase 65 Combination REOLYSIN R 65 biliary tract cancer 65 Milatuzumab 65 aerosolized AAT 65 ZACTIMA 65 interleukin IL -# 65 AAG geldanamycin analog 65 JAK inhibitors 65 Pertuzumab 65 oral JAK#/JAK# inhibitor 65 Peginterferon alfa 2b 65 LymphoStat B TM 65 Dapagliflozin 65 Azedra 65 bardoxolone 65 Cloretazine ® 65 Neulasta R 65 Severe Sepsis 65 LUX Lung 65 highly selective inhibitor 65 Pegloticase 65 Anthracycline 65 intravesical instillation 65 cell lymphoma CTCL 65 soluble tumor necrosis 65 metastatic hormone refractory 65 PXD# 65 Taiho Pharmaceutical 65 Urocidin TM 65 liposomal formulation 65 Metastatic Melanoma 65 Ofatumumab 65 Squalamine 65 Initiates Clinical Trial 65 LHRH antagonists 65 Neulasta ® 65 Trastuzumab DM1 65 intravesical infusion therapy 65 alvespimycin 65 NS5b 65 investigational humanized monoclonal antibody 65 Phase 2b Study 65 RNAi Therapeutic 65 Genasense ® 65 induced macular edema 65 Elagolix 65 Monoclonal Antibody 65 JAK inhibitor 65 depsipeptide 65 apaziquone 65 Gastric Cancer 65 Phase 2b Trial 64 Bafetinib 64 dasatinib Sprycel 64 IgG1 monoclonal antibody 64 ospemifene 64 castrate resistant prostate cancer 64 Phase IIb Trial 64 PEGylated anti 64 MKC# MKC# PP 64 relapsed multiple myeloma 64 pralatrexate injection folate analogue 64 Pivotal Phase 64 Janus kinase 64 Allovectin 7 64 essential thrombocythemia ET 64 Vidaza azacitidine 64 Patients Treated With 64 Eculizumab 64 PGL# 64 Mycophenolate Mofetil 64 elotuzumab 64 ELACYT 64 Brentuximab Vedotin SGN 64 MKC# MT 64 Therapeutic Vaccine 64 docetaxel Taxotere R 64 Actimmune ® 64 Tanespimycin 64 MEK inhibitors 64 ceftazidime 64 ALN HPN 64 ADP receptor antagonist 64 Phase III Trial 64 Tigecycline 64 Behcet uveitis 64 investigational oral inhibitor 64 Onalta TM 64 Mucosal 64 Anthracyclines 64 Exherin TM 64 Zorbtive TM 64 Factor Receptor 64 Curaxin 64 TEMODAL 64 proteasome inhibitor 64 paclitaxel Taxol 64 lexidronam injection 64 LymphoStat B belimumab 64 Factor VIIa 64 Gemcitabine 64 IMC A# 64 refractory cutaneous T 64 Enzastaurin 64 immunomodulatory properties 64 small molecule Hedgehog 64 methylnaltrexone bromide 64 HDACi 64 multiple myeloma MM 64 refractory prostate cancer 64 vinca alkaloid 64 Melphalan 64 Pivotal Trial 64 Mitomycin C 64 thetreatment 64 davunetide intranasal AL 64 non nucleoside 64 trabectedin 64 Gleevec resistant 64 Hepatocellular Carcinoma HCC 64 Pharmacokinetics PK 64 alpha#beta# integrin 64 Initiate Phase 64 vinorelbine tartrate 64 Civacir 64 Signaling Pathway 64 Camptosar ® 64 MEK inhibitor 64 Valopicitabine 64 Bleomycin 64 mitogen activated ERK kinase 64 Vandetanib 64 tubulin inhibitor 64 Dalbavancin 64 PEGylated Fab fragment 64 Tipranavir 64 PDX pralatrexate 64 DermaVir Patch 64 PDE4 64 Liposomal 64 unique alkylating agent 64 sodium glucose cotransporter 64 PNP inhibitor 64 Allovectin 7 ® 64 5 HT6 receptor 64 Completes Patient Enrollment 64 pathophysiological effects 64 Raptiva ® 64 vinca alkaloids 64 PI3K/Akt pathway inhibitor 64 Cardiomyocytes 64 Nitazoxanide 64 Raptiva R 64 antibody MT# 64 Zalypsis 64 Quinamed 64 TH# [003] 64 Bazedoxifene 64 Lenocta 64 NDA Submission 64 radiolabeled TM# 64 orally administered inhibitor 64 HCD# [002] 64 fallopian tube cancers 64 rasagiline tablets 64 budesonide foam 64 cetuximab Erbitux R 64 SPRYCEL ® 64 Prodrug 64 acadesine 64 oral proteasome inhibitor 64 ORENCIA ® 64 Clinical Trial Results 64 Soft Tissue Sarcoma 64 IAP inhibitor 64 apoptosis inducer 64 5 HT4 64 Davunetide 64 Phase Ib clinical trials 64 Androgen Receptor 64 refractory chronic lymphocytic 64 sorafenib Nexavar 64 TNF Tumor Necrosis Factor 64 Alocrest 64 Squamous 64 Luteinizing Hormone Releasing Hormone 64 Talactoferrin 64 secondary hyperparathyroidism 64 R sorafenib tablets 64 Seliciclib 64 Lenalidomide 64 sunitinib malate 64 riociguat 64 MyVax R 64 Lupus Nephritis 64 Tyrosine Kinase Inhibitor 64 NPM1 mutation 64 Dose Escalation 64 cinacalcet HCl 64 ISTODAX 64 advanced hepatocellular carcinoma 64 cutaneous T 64 Chemokine Receptor 64 hepatitis C HCV 64 Lenocta TM 64 Leukemias 64 Combination Therapy 64 myeloproliferative diseases 64 TRISENOX ® 63 rhMBL 63 Relapsed Refractory 63 relapsing remitting MS RRMS 63 interferon gamma 1b 63 Medoxomil 63 polycythemia vera essential thrombocythemia 63 Phase 1b Clinical Trial 63 Phase 2a Clinical Trial 63 IV Busulfex 63 G#DT 63 eritoran 63 Naive Patients 63 small molecule thrombopoietin 63 either acutely decompensated 63 Pfizer Sutent 63 Investigational Agent 63 Preclinical Models 63 relapsed MM 63 Navelbine ® 63 solithromycin 63 ZD# [001] 63 prostate cancer AIPC 63 Faropenem 63 Sudhir Agrawal D.Phil 63 anti EGFR antibody 63 CBLC# 63 Pazopanib 63 Romidepsin 63 Ibritumomab Tiuxetan 63 targeted radiotherapeutic 63 vapreotide acetate 63 alpha#beta# 63 effector function 63 Patient Enrollment 63 R#/MEM 63 polymerase inhibitor 63 IgG1 antibody 63 Friedreich Ataxia FRDA 63 BARACLUDE R 63 Investigational Drug 63 Enzyme Replacement Therapy 63 alkylating agent 63 Gastrointestinal Stromal Tumors 63 myeloproliferative disorders 63 reslizumab 63 anticancer compound 63 Evoltra ® 63 IMiDs ® 63 Interferon Gamma 63 advanced metastatic renal 63 Panzem R 63 ixabepilone 63 Decitabine 63 Budesonide MMX 63 Cellegesic 63 Tavocept 63 BCG refractory carcinoma 63 androgen receptor AR 63 Antiviral Activity 63 complement inhibitor eculizumab 63 DNA intercalator 63 histone deacetylase inhibitor 63 Gefitinib 63 refractory multiple myeloma 63 Debio 63 monoclonal antibody conjugated 63 colorectal carcinoma 63 lucinactant 63 cytostatic 63 Achieves Primary Endpoint 63 oral deforolimus 63 Aurora kinase 63 terlipressin 63 Chronic Hepatitis B 63 Tesetaxel 63 FASLODEX 63 benign prostatic hypertrophy BPH 63 Silodosin 63 TLK# 63 Colorectal Cancer Patients 63 plasma kallikrein inhibitor 63 Inhalation Solution 63 Microplasmin 63 Parathyroid Hormone 63 Pathway Inhibitor 63 relapsed leukemia 63 orally dosed 63 busulfan 63 Thiovir 63 Ixempra 63 vascular disrupting agents 63 XL# XL# XL# 63 imatinib Gleevec ® 63 Carfilzomib 63 acetonide FA 63 ularitide 63 Serostim ® 63 Calcitonin 63 Zollinger Ellison Syndrome 63 CR# vcMMAE 63 Taxane 63 Trial Evaluating 63 Dasatinib 63 Monotherapy 63 Tumor Targeting 63 NP2 Enkephalin 63 chemotherapy cisplatin 63 Mg Uk 63 Nimotuzumab 63 toenail onychomycosis 63 humanized monoclonal 63 Tumor Response 63 denileukin diftitox 63 Phase IIa Clinical Trial 63 Randomized Phase II 63 PSN# [002] 63 erlotinib Tarceva 63 Efficacy Trial 63 Receives Orphan Drug 63 vascular disrupting agent 63 TKB# 63 #D#C# 63 vidofludimus 63 Single Dose 63 selective kinase inhibitor 63 ThermoDox ® 63 HQK 63 MOVIPREP R 63 poly ADP ribose polymerase 63 papillary renal cell carcinoma 63 Initiates Enrollment 63 Epstein Barr Virus EBV 63 dependent kinase inhibitor 63 BrachySil 63 gemcitabine Gemzar 63 immunotherapeutic agent 63 TRO# 63 paclitaxel Taxol ® 63 Moxifloxacin 63 p# biomarker 63 PROSTASCINT R 63 Akt inhibitor 63 selective modulator 63 mesylate 63 EndoTAG 63 APTIVUS 63 metastatic GIST 63 CIMZIA ™ 63 R#/MEM # 63 Panzem NCD 63 Simulect 63 Ciclesonide 63 Glypromate 63 HGS ETR2 63 thalidomide Thalomid 63 tenofovir disoproxil fumarate Viread 63 Kinase Inhibitors 63 Fludara ® 63 Solazed TM 63 CIMZIA TM 63 D aspartate NMDA receptor 63 ara C 63 PRTX 63 Diabetic Neuropathy 63 Renal Cell Carcinoma 63 preclinically 63 Bezielle 63 Talabostat 63 Cytochrome P# 63 Copegus ribavirin 63 prasterone 63 Randomized Phase 63 alefacept 63 Onco TCS 63 Chronic Myeloid Leukemia 63 unresectable stage 63 Taxotere ® 63 Phase 1b clinical trials 63 samarium Sm 63 Improved Survival 63 eIF 4E 63 GATTEX TM 63 Xeloda ® 63 Initiates Phase III 63 2 inhibitor CYT# 63 Velcade bortezomib 63 Atypical Hemolytic Uremic Syndrome 63 HuMax 63 pain palliation 63 Antiviral Therapy 63 Bicalutamide 63 CCR9 antagonist 63 rALLy clinical trial 63 RhuDex ® 63 Diamyd ® 63 humanized anti 63 Disease Progression 63 Novel Antibiotic 63 paclitaxel poliglumex 63 invasive candidiasis 63 Omacetaxine 63 Acute Ischemic Stroke 63 Tarceva TM 63 atypical Hemolytic Uremic Syndrome 63 Improves Survival 63 Retinoic Acid 63 multikinase inhibitor 63 VALSTAR 63 Allovectin 7 R 63 metastatic gastric 63 Interferon Beta 63 ALN TTR 63 Secretase 63 Etoposide 63 HGS ETR1 mapatumumab 63 constipation OIC 63 BZL# 63 epothilone 63 peptidic compound 63 Virulizin R 63 Sym# 63 nucleoside analogues 63 Prospective Randomized 63 Neoadjuvant 63 histamine dihydrochloride 63 anticancer agent 63 Vidaza ® 63 cutaneous T cell 63 Dupuytren Contracture 63 QUADRAMET R 63 AV HALT 63 TAFA# 62 HuMax CD4 62 luliconazole 62 Microspheres 62 Maribavir 62 LHRH antagonist 62 vemurafenib 62 Clevudine 62 CCR5 mAb 62 cilengitide 62 Initiate Phase II 62 GRASPA ® 62 rxRNA 62 R lenalidomide 62 Multiple Ascending Dose 62 Oral Mucositis 62 BRIM2 62 Alinia 62 FGFR2 62 tramiprosate Alzhemed TM 62 ATL/TV# 62 tanespimycin 62 Dacogen injection 62 methylnaltrexone 62 antiangiogenic therapy 62 Fast Track Status 62 CYT# novel 62 carcinoma HCC 62 Telbivudine 62 Ixabepilone 62 indibulin 62 Ranolazine 62 Provectus Pharmaceuticals specializes 62 alpha folate receptor 62 refractory CTCL 62 MT#/MEDI-# 62 gemcitabine Gemzar ® 62 C1 Inhibitor 62 Inhalation Aerosol 62 HCV protease inhibitors 62 Cx# [002] 62 ASONEP 62 CD# antibody [001] 62 JAK3 62 including eniluracil ADH 62 noninfectious uveitis 62 microtubule inhibitor 62 antisense inhibitors 62 Vidaza R 62 PROCHYMAL 62 cMET 62 Saizen ® 62 PDE4 inhibitor 62 Newly Diagnosed Multiple Myeloma 62 Diffuse Large B 62 Vaprisol 62 ZYBRESTAT fosbretabulin 62 HGS ETR1 62 farletuzumab 62 GV# [001] 62 tubulin binding 62 Anti Tumor Activity 62 LHRH receptor positive 62 mTOR mammalian target 62 IRESSA 62 thymalfasin 62 Vorinostat 62 Survival Benefit 62 pharmacokinetic interactions 62 NS5B polymerase 62 FDA APPROVES 62 Files IND 62 Bendamustine 62 PHX# 62 ALS #-# 62 FUSILEV ® 62 Protelos R 62 efalizumab 62 goserelin 62 JVRS 62 GVAX ® 62 dacarbazine DTIC 62 Azacitidine 62 plus DOXIL 62 Onalta 62 nilotinib Tasigna 62 oncolytic virus therapies 62 monoclonal anti 62 VAPRISOL 62 Palonosetron 62 posaconazole 62 Guanilib 62 Saforis 62 investigational monoclonal antibody 62 R roscovitine 62 Well Tolerated 62 Ganciclovir 62 Androgen Deprivation Therapy 62 Pegylated 62 Progenitor Cells 62 antisense inhibitor 62 LEUKINE 62 Cloretazine R 62 potent topoisomerase II 62 Kepivance 62 Randomized Study 62 T#I [002] 62 SIR Spheres 62 EGFR inhibitors 62 Belinostat 62 generation Hsp# inhibitor 62 TASQ 62 Diabetic Nephropathy 62 ProLindac TM 62 Lymphocytic 62 fosbretabulin 62 RNAi Therapeutics 62 Pharmacokinetic Study 62 Brain Metastases 62 hypoxia inducible factor 62 alfa 2a 62 LEP ETU 62 TNF alpha selectively neutralizing 62 Shows Promise Against 62 cancer vaccine Norelin 62 Aganocide 62 Romiplostim 62 anti inflammatory NSAID 62 Fodosine 62 immune modulatory 62 sublingual tablets 62 CA4P 62 potent antiproliferative 62 MGN# 62 Initiate Phase III 62 Albuferon TM 62 Oncogenic 62 ancrod 62 miconazole Lauriad ® 62 Tesmilifene 62 beta 1a 62 polycythemia vera PV 62 Oncolytic 62 systemic fungal infections 62 Sezary syndrome 62 Valsartan 62 Gamunex C 62 gemcitabine carboplatin 62 Rectogesic 62 Dose Ranging Study 62 drug conjugate 62 multi kinase inhibitor 62 Medullary Thyroid Cancer 62 Complicated Skin 62 HCV polymerase 62 P#X# 62 OHR/AVR# 62 idiopathic myelofibrosis 62 RH1 62 Akt activation 62 SERMs 62 androgen independent 62 Trastuzumab 62 Protexia R 62 TELINTRA 62 Tyrima 62 MKC# 62 PF # [001] 62 Telatinib 62 elacytarabine 62 Bucindolol 62 CD3 monoclonal antibody 62 ATL# [001] 62 Fluorouracil 62 accumulate preferentially 62 zanolimumab 62 Previously Treated 62 Pooled Analysis 62 Inflammatory Diseases 62 INTEGRILIN R 62 HGS# 62 Mg Usa 62 NPC 1C 62 BCG refractory 62 Trabectedin 62 Kahalalide F 62 BioNumerik 62 MT# MEDI 62 Preclinical Data 62 Hycamtin 62 OncoVEX GM CSF 62 Symadex 62 Myelofibrosis 62 Palifosfamide 62 metastatic castrate resistant 62 Cotara ® 62 selective immunoproteasome inhibitor 62 Capecitabine 62 topical NSAID 62 luteinizing hormone releasing 62 GTC recombinant human 62 enzastaurin 62 PRT# 62 Bronchiectasis 62 non nucleoside inhibitor 62 Vaccine Candidate 62 Gemzar ® 62 Antiangiogenic 62 histone deacetylase HDAC inhibitors 62 aurora kinase 62 Atripla combines 62 Fibroblast 62 brand ciclesonide HFA 62 sarcoma melanoma 62 HCV NS5B polymerase 62 erlotinib Tarceva R 62 sapacitabine CYC# 62 CCX# 62 gastro intestinal inflammation 62 Phase IIb Clinical Trial 62 evaluating tivozanib 62 CYP#A# CYP#D# 62 Systemic lupus erythematosus SLE 62 afatinib 62 Fresenius Biotech 62 NEBIDO R 62 trastuzumab DM1 62 CD4 monoclonal antibody 62 AVAPRO 62 Pegylated Interferon 62 sunitinib Sutent ® 62 biologic therapy 62 anti amnesic 62 gastric adenocarcinoma 62 Temsirolimus 62 Anticancer Compound 62 Advanced Solid Tumors 62 SCCHN 62 EndoTAG TM -1 62 nucleoside reverse transcriptase inhibitor 62 Ecallantide 62 Chronic Lymphocytic Leukemia 62 Erlotinib 62 Aclidinium 62 Taxotere docetaxel 62 uricase 62 TACI Ig 62 OMP #R# 62 SNT-MC#/idebenone 62 monoclonal antibody mAb 62 Nanobody 62 vorinostat 62 galiximab 62 systemic anaplastic large 62 synthetic retinoid 62 DAVANAT 62 docetaxel Taxotere 62 hypoxia activated prodrug 62 antitumor effect 62 amrubicin 62 DOXIL 62 Phase IIA 62 Interferon beta 1a 62 HSP# inhibitor 62 Campath ® 62 Sunesis Pharma 62 Omacor ® 62 LibiGel ® 62 Tarvacin 62 TheraCIM 62 Eniluracil 62 orally bioavailable 62 Pulmonary Arterial Hypertension 62 IIa Clinical Trial 62 Xyfid TM 62 Tacrolimus 62 opioid induced bowel dysfunction 62 Elvitegravir 62 Pivotal Clinical Trial 62 BCIRG 62 tumors GIST 62 drug pipeline TAFA# 62 mGluR5 NAM 62 novel anticancer 62 #I TM# 62 LUCASSIN 62 Preclinical Study 62 REMINYL ® 62 Anticancer Activity 62 BENLYSTA ® 62 Etanercept 62 Advanced Pancreatic Cancer 62 adalimumab Humira 62 CYC# 62 ganetespib 62 Cleviprex TM clevidipine 62 lapatinib Tykerb 62 TO AVOID PREGNANCY WHILE 62 5 Fluorouracil 62 candidates Azedra TM 62 PEG SN# 62 HER2 positive metastatic breast 62 VitiGam 62 TLR9 agonist 62 Xeloda capecitabine 62 Docetaxel 62 Ceflatonin 62 Antigen Specific 62 Gliadel Wafer 62 Sanvar R 62 SAR# [002] 62 Icatibant 62 Study Evaluating 62 Hycamtin ® 62 ATG Fresenius S 62 Multicenter Randomized 62 Receives Marketing Authorization 62 Adjuvant Therapy 62 relapsed refractory multiple myeloma 62 Plasmin 61 Myelodysplastic Syndromes 61 Pivotal Study 61 recurrent glioma 61 Peginterferon 61 Phase Ib study 61 Catena ® 61 Zonisamide 61 VELCADE melphalan 61 antiproliferative effects 61 trabedersen 61 novel emulsion formulation 61 Glufast 61 Protease Inhibitor 61 Cardiotoxicity 61 OvaRex ® MAb 61 quinolone 61 Wafer polifeprosan 61 pegylated liposomal doxorubicin 61 trastuzumab Herceptin R 61 tumor necrosis 61 Orphan Status 61 tumor vascular disrupting 61 Deforolimus 61 Glioma 61 Saizen R 61 multicenter Phase II 61 mGluR2 NAM 61 Trodusquemine MSI 61 Mipomersen 61 CINTREDEKIN BESUDOTOX 61 nucleoside analogue 61 HCV Protease Inhibitor 61 Fibrillex TM 61 LB# [003] 61 hepatitis B HBV 61 Initiates Phase 61 stage IIIB 61 SinuNase ™ 61 5 HT6 61 OncoGel 61 plasmid encoding 61 Preclinical Efficacy 61 5alpha reductase 61 Neuroprotection 61 Teriflunomide 61 TMC# C# 61 Amplimexon 61 ritonavir boosted 61 BIBW 61 Erbitux cetuximab